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Abstract 
Human pluripotent stem cells (hPSCs) have the potential to transform medicine. However, hurdles remain to 
ensure safety for such cellular products. Science-based understanding of the requirements for source materials 
is required as are appropriate materials. Leaders in hPSC biology, clinical translation, bio-manufacturing and 
regulatory issues were brought together to define requirements for source materials for the production of hPSC-
derived therapies and to identify other key issues for the safety of cell therapy products. Whilst the focus of this 
meeting was on hPSC-derived cell therapies, many if the issues are generic to all cell-based medicines. The intent 
of this report is to summarise the key issues discussed and record the consensus reached on each of these by 
the expert delegates. 
1. Introduction 
Before new regenerative medicine therapies (RMTs) can be routinely applied, their efficacy and safety must be 
assessed in preclinical models and then in man. A key step in this is defining the essential safety assessment 
criteria in the manufacturing process to enable reliable rapid translation of treatments with potential. This 
requires consensus between stakeholders on the issues. This is particularly so for the case of new and evolving 
therapies such as cell based regenerative medicinal therapies (RMT). Consequently, the UK Regenerative 
Medicine Platform (UKRMP)1 ‘cell behaviour, differentiation and manufacturing hub’ (known as the Pluripotent 
Stem Cell Platform (PSCP)) and the UKRMP the ‘safety and efficacy hub’ organised an inaugural workshop. This 
brought together scientists from all five UKRMP hubs, regulators, industry and other stakeholders, to develop a 
clearer understanding of the potential hazards to inform the UKRMP programme on the new methodologies 
needed to assess and control these risks. 
2. Differences between Cell-based Medicines/RM and Conventional Medicines: Establishment of the 
Unique Features. 
 
RMT development is moving from a lab-based experimental discipline to a nascent industry anticipated to 
provide a diverse range of complex RMT products to a large market. This drives a need for robust manufacturing 
                                                          
1 The UK Regenerative Medicine Platform (UK RMP) supports scientific ‘Hubs’ to provide new tools, protocols 
and resources with broad applicability across regenerative medicine.  For information see 
http://www.ukrmp.org.uk/   
systems for cell-based products that meet the scalability and regulatory compliance demands of medical product 
manufacture. 
Such living products pose new challenges when compared to conventional pharmaceuticals – in particular, they 
cannot be sterilised prior to use to provide a robust physical barrier to potential contamination being 
transmitted to patients. Cell-based products are complex and constantly interacting with, and responding to 
their environment. Thus, maintaining consistent product efficacy requires precise process definition and control 
and avoidance of adverse changes in heterogeneous populations and the cell environments. The measurement 
of product quality for a living cell population is difficult and typically is based on average population values of 
surrogate markers that are at best indicative of critical product attributes. The inherent pluripotency and 
potential plasticity of stem cells makes quantifying their properties even more challenging. 
The solutions developed for conventional biologics manufacture cannot readily be applied directly to cell-based 
products. The propensity of therapeutic cells to be affected by their environment, the requirement for aseptic 
manufacturing, the need to accommodate biological variation (Thurman-Newell, et al., 2014) and the difficulties 
of quantitative cell-based product measurement (see below) have enforced greater reliance on process 
understanding and control to guarantee product safety and efficacy. Consistent compliant GMP manufacturing 
requires reproducibility and comparability following any change, with a focus on Safety, Efficacy and Quality. 
Key issues include: raw material and starting material control, cell banks assuring robust and safe production 
chains, in process controls and evaluation, and specification of final products.  From a product regulation 
perspective, purity, identity, and potency are the central issues for biological medicine safety and efficacy. 
However, definitions for these measurable quantities are still developing for cell-based RMTs. These specific 
knowledge gaps were explored in another workshop reported by Williams et al., 2016.. 
Finally, established biologicals derived using cells as “factories” typically employ one cell line to manufacture 
each product, however, for RMTs the need to avoid adverse immunological reactions and long term immune-
suppression is likely to require lines from multiple donors to achieve a degree of immunological matching. While 
the number of lines required to develop appropriate therapies is still emerging, RMT products are currently 
being developed with small numbers of lines future-proofed for use in clinical trials (1, 2). These initiatives may 
require strategic international collaboration (Barry et al., 2015; Turner et al., 2013) but presently, the field is not 
yet equipped to use the number of lines needed to achieve broad healthcare benefits. The necessary progression 
to additional lines will require careful demonstration of product comparability which is a focus of the work of 
PSCP (Williams et al., 2016). 
Finally, the criteria critical to assessment of RMT potency are at an early stage of development while 
bioprocessing progresses rapidly. Thus, gathering data on biological variability as clinical experience grows will 
be important to support and enhance the development of RMT manufacturing. 
3. Current Guidance on Raw and Starting Materials. 
The sourcing and qualification of raw materials used to make a product is crucial to product quality and safety 
and was the subject of a dedicated session at the workshop. The quality of those of biological origin is often 
variable and product developers currently lack guidance in this area. Under European regulation definitions (i.e. 
EC, 2001 and EDQM, 2013) raw materials are substances used for manufacturing but from which the product is 
not directly derived and distinct from starting materials which are materials from which the active substance is 
manufactured. The regulatory requirements for the quality of raw and starting materials used in the 
manufacture of ATMPs are captured in the IMPD for clinical trials and in the marketing authorisation process 
document. 
There are two documents recently developed in Europe, that aim to support regulatory guidance documents in 
the assessment of raw materials for use in the manufacture of cell-based medicines. These are intended to give 
additional guidance to manufacturers and help to harmonise standards. The European Medicines agency (EMA) 
and the European Directorate for the Quality of Medicines and Healthcare (EDQM) have produced a draft 
guidance document (European Pharmacopeia, 2016) covering suitability of raw materials for intended use, 
consistency of product, specification of material and acceptance criteria. It also recommends a risk based 
approach to assess and control the impact of the quality of a raw material on the ATMP.  The second is a British 
Standards Institute (BSI) publically available specification (PAS); PAS 157 ‘Evaluation of materials of biological 
origin used in the production of cell-based medicinal products’ (PAS157, 2015, and weblink 5). This has been 
drafted to complement European Phamacopoeia General Chapter on raw materials for gene and cell therapy 
(2016). Different terminology is used in the USA, where the Pharmacopeia (USP) has used the term ancillary 
materials (AMs) for which a defining property ‘is that they are not intended to be present in the final product’ 
and includes in this category many cell culture reagents (USP, 2014).  
These documents provide guidance and information on risk based processes and important aspects to consider 
in the selection and use of raw and ancillary materials. However, they are written from different perspectives 
and should be used as complementary references as outlined in Table 1. 
 
Table 1. Comparison of guidance on raw materials 
Guidance Purpose Applicability 
EDQM (General Chapter 
5.2.12) 
Guidance on general 
approach to RMTs to 
meet EU legislation 
Raw materials i.e. those which are not intended to 
form part of the product  
USP “Ancillary Materials” This chapter addresses 
such topics as the 
qualification of ancillary 
materials, risk 
classification, 
performance testing and 
removal of residual AMs. 
Plasma-or serum-derived products, biological 
extracts, antibiotics, cytokines, culture media, 
antibodies, polymeric matrices, separation 
devices, density gradient media, toxins, 
conditioned media supplied by “feeder cell 
layers”, fine chemicals, enzymes and processing 
buffers’ 
BSI PAS157 Guidance on raw 
materials of animal origin 
Guidance on defining raw materials from the 
quality and regulatory perspectives, points to 
consider in the selection and characterisation of 
raw materials, supplier evaluation and relevant 
regulatory and legislative frameworks. 
 
4. Starting Materials 
Starting materials, such as cells, genetic vectors and scaffolds, demand special attention in safety assessment 
as, in contrast to raw materials, they persist in the patient. Starting materials such as a cell preparation are a 
significant source of variability in the final product and a deep understanding of them is required for delivery of 
effective and consistent RMTs. The primary safety considerations for starting materials relate to donor cells and 
other components which modify the cells including genetic vectors and scaffolds and key issues are outlined in 
Table 2.  
A crucial difference between starting materials for cell therapy and other medicines are the donor cell issues 
and guidance has been published recently (DH, 2014 and website 3) on infectious hazards, genetic predisposition 
to disease and consent for use in cell therapy (see Table 2). It was noted that more than 70 human pathogens 
have been identified in transplantation and the range of potential contaminants increases with the use of cell 
culture raw materials of biological origin. Next generation sequencing presents an opportunity to screen for any 
contaminant organism and the need to assure the veracity and value of such data is already being addressed 
within the PSCP.  Cell-based products may persist in the recipient for decades which has consequences for 
patient monitoring and risk, and retention of manufacturing records.  The development of cell history files (see 
Andrews et al., 2015) for seed stocks of cell lines was discussed as a valuable, although not mandatory, approach 
to provide full documentation and traceability for cell lines. They have potentially significant value in 
accelerating product development, reducing characterisation overheads and enable the potential use of 
multiple cell lines for a common production process. The workshop delegates also identified a requirement for 
further discussion on safety relating to genetic modification and scaffolds. 
Table 2. Safety of starting materials 
Key Issues Context Mitigation 
Donor tissues: 
Donor selection/screening and 
traceability  
Base risk assessment on 
donor selection process 
regarding infectious and 
cancer hazards and potential 
adverse genetic traits 
 
Robust traceability, risk assessment and 
“lookback” procedures (N.B. to include 
confirmation of fully-informed consent) 
including likely hazards from tissue of 
origin  
Investigation of genetic traits in donor 
cells may not be helpful but might be 
applied to a cell line. 
Pre-donation medical history and post 
donation donor interview and screening. 
Consider supplementary testing as 
indicated by risk assessment. 
General reference: DH, 2014.  
Cell line derivation: 
Media quality, including purity 
and identity 
Vectors used and genetic or 
epigenetic modification 
Banking procedure (passaging 
cryopreservation and stability) 
Exposure to adventitious 
agents or other factors which 
could adversely alter the cells 
Cell culture drift- genetic 
instability 
Vector integration effects 
Vector DNA in final product  
Dialogue with manufacturers to improve 
traceability and suitability of media and 
vectors 
Analysis of vector sequence and 
incorporation of vectors in cells (e.g. copy 
number, integration, integrity) or 
confirmation of their removal  
Pre-use acceptability tests 
Scaffolds: 
Biological origin e.g. human, 
animal, plant, microbial 
Novel synthetic materials 
Exposure to adventitious 
agents 
Induction of cellular changes 
due to cell-matrix 
interactions 
Suitable source materials 
Leachates  
Degradation products 
Traceability and risk assessment of source 
materials and consider supplementary 





5. Safety Issues in Biomanufacturing 
 
5.1 Cell Differentiation 
Converting undifferentiated cells into therapeutic cell preparations is a complex and lengthy multi-step 
manufacturing process, typically emulating natural developmental pathways (for example Murry et al., 2008). 
Key considerations for the safety and efficacy of these products are the need to minimise the risk from microbial 
contamination during culture processing and the risk of creating inappropriate or dysfunctional cells. In order to 
generate simpler and more efficient delivery of the product, approaches may be employed using small molecules 
to artificially direct cell differentiation. These will need qualification to assure that they do not lead to increased 
risk of adverse events. Other approaches to reduce risk may include the creation of physical stop/go points such 
as cryopreservation of early proliferative progenitor phases and in process control testing to assure that the 
differentiation process is consistent throughout. Qualification of such procedures is a major focus of the PSCP 
bioprocessing work.  
Current protocols for hESC and hiPSC differentiation are widely acknowledged to yield cells of fetal phenotype 
(e.g. Hrvatina et al., 2014; van den Heuvel et al., 2014) which may not provide optimal cells for therapy in adult 
tissue. This is a major hurdle for the field which will require ongoing research to resolve.  
A further challenge for hPSC-described products is that mixed cell types may arise in the differentiation protocol, 
such as glial cell populations in neuronal differentiation. Where it is not possible to increase cell purity through 
protocol development a cell purification step may be required. Where a physical cell purification step is used 
the predictability and consistency of the outcome to deliver a pure population of cells, must be understood. The 
purity of the final therapeutic cell preparation and the nature of any “contaminant” cells which may include both 
‘off-target’ differentiated cells and undifferentiated stem cells, will be important factors to consider and 
understand. These factors will also be important considerations throughout bioprocessing including, the banked 
intermediate cultures, in process progenitor cell populations and the final product. 
5.2 Genetic Stability 
It is clear that genetic and epigenetic stability needs to be better understood.  Currently, the impact of any 
evident genetic changes may be evaluated on a case by case basis and approaches to address this in cell line 
seed stocks and the potential impacts of adverse genetic traits have been discussed elsewhere (e.g. Andrews et 
al., 2015; DH, 2014).  Genetic changes may be neutral mutations with no immediate impact, while others may 
stabilise hPSC cultures and facilitate in vitro maintenance. However, in the context of RMTs, of particular concern 
are genetic changes that may lead to cell transformation and potentially could give rise to tumorigenic cells. The 
PSCP is already beginning to work on these issues and has initiated a workshop series which has dealt with these 
issues in detail (Andrew et al., 2017). 
 
5.3 Tumourigenicity (in vivo and in vitro techniques and biomarkers) 
The increasing capability to study genetic variants shows that these can be observed in all cell lines 
and absolute genetic stability is not likely to be achievable. Genetic changes that enhance proliferation 
of undifferentiated cells can promote expansion of abnormal cells at the expense of the original cells, 
and such clones can dominate the culture within a few passages. Furthermore, mutations of no 
apparent significance in undifferentiated cells could impact on the behaviour of differentiating 
progeny, potentially causing adverse biology including malignancy. There is no data on mutation rates 
of different loci in cells; but changes in culture are known to give rise to large, non-random 
chromosomal changes (commonly affecting chromosome 12, 17 and 20q gains in hESC and hiPSC lines 
(Amps et al., 2011). 
Pluripotent stem cells typically grow as benign teratomas in immune-deficient mice but may also 
create potentially malignant teratocarcinomas. Numerous features of cell preparation and host 
factors influence the detection of tumourigenicity in animal models and these must also be considered 
in assessing the tumorigenic potential of residual undifferentiated cells in RMTs. Purity of cell 
populations in a therapeutic product will be challenged by regulators and there may be an expectation 
to validate zero undifferentiated hPSCs in the final product. This will be extremely demanding to 
demonstrate, and may also require a risk-benefit decision to be made on a case by case basis. In the 
short term, a pragmatic position on genetic changes will need to be adopted for the culture of hPSCs 
intended for clinical applications (Andrews et al., 2015; Kim et al., 2017), but more data is needed on 
which variants are important for safety. 
5.4 Phenotypic Stability 
Delegates agreed that researchers are unlikely to make a perfect replica of the native cell type to be 
replaced, but aim to create one which could deliver the anticipated benefit to the patient. Knowledge 
of cell populations and the impact of non-cellular impurities, whether involving significant changes or 
intermediate cellular states that stabilise in vitro culture should be identified, and compromised cells 
eliminated. A key conclusion from discussion was that it is crucial to establish a strong scientific 
understanding of the phenotypes of cell populations in the product. This will also inform regulators 
about the veracity of proposed quality control, in-process testing to assure consistency of cell banks, 
the product quality attributes and maintenance of comparability when changes are introduced. 
Comparability and selection of appropriate indicators of sustained functional capacity was the subject 
of another PSCP workshop(Williams et al., 2016). 
6 Modelling Interactions between Therapeutic Cells and Recipients 
Once administered into the patient, efficacy issues hinge on measurement of function, numbers of 
cells to deliver function and determination of whether other contaminant cells are detrimental. Pre-
clinical models are crucial to elucidate the key efficacy and safety factors. Understanding of the 
potential for cell migration of implanted cells, their destinations in the recipient and the impact of 
patient variation are also critical. 
6.1 Immunology 
Host immune responses can represent a formidable obstacle. In particular, allogenic, transplanted 
cells will have different degrees of major histocompatibility antigen (MHC) mismatch with the 
recipient and risk immune rejection. Even when donor and recipient are MHC matched, a number of 
other antigen dependent rejection mechanisms can be activated. In addition, antigen-independent 
inflammatory pathways modulate endogenous repair and can hinder donor cell engraftment and 
potentiate the adaptive immune response mediating graft rejection. Adverse reactions may also arise 
from drug-induced immunosuppressant approaches. Use of bone marrow mesenchymal stromal cells 
(MSCs) which do not normally express HLA class II and have immunosuppressive activity, are less likely 
to cause concern, however convincing efficacy data has been elusive.  To accelerate community 
learning, clinical use and risk minimisation, information sharing in “safe” fora is desirable for trials in 
progress. 
6.2 Imaging analysis including, transplant technique, bio-distribution, repeat dosing and ectopic 
engraftment 
It is of particular importance to be able to monitor and track cells when transplanted to assess whether 
any cells take residence in inappropriate areas. Imaging techniques may be able to indicate if any 
potentially detrimental effects are observed on, or off-target, and provide such safety data.  
Nanoparticle labels show promise in tracking RMTs as contrast agents for different imaging 
techniques. Some are approved for clinical use (Heslop et al., 2015), but do not currently have the 
sensitivity required to track transplanted cells in pre-clinical studies or clinical trials. Delegates 
believed that long-term stable nanoparticles with superior signal intensity, uptake behaviour, stability 
and retention are required. Nanoparticle evaluation tests ensure that, once introduced, they do not 
cause damage or change in function of cells. Labelled stem cells are tracked in rodent models using 
multi-modality imaging techniques to determine a) the most appropriate imaging technique; b) the 
sensitivity of the labelled cells and; c) where the cells are bio-distributed in the body, evaluating 
potential safety risks, and indicating the relationship between disposition and function (Scarfe et al., 
2017). Safety hub researchers stated that, particularly for stem cells and macrophages, imaging 
modality and labels are cell type dependent; for example stem cell labelling with reporter genes, 
nuclear markers for whole body and bioluminescence imaging to validate organ targeting. Cells 
containing tracking probes can also be translated back from man to determine if preclinical models 
are appropriate. Imaging in real-time as cells are administered shows disposition related to effect 
through functional markers, delivering a preclinical platform for physiology, pharmacology and 
toxicology of cells for regenerative medicine. A key goal for imaging safety techniques must be to 
develop methods that permit tracking of very small numbers of cells and ideally single cells. 
7 Characterisation and Measurement. 
 
7.1 General considerations 
The detailed characterisation of final product is critical and whilst there is regulatory guidance, the 
technical requirements are the primary responsibility of the overseeing scientists. Many so-called MSC 
clinical trials worldwide are characterised by a limited number of phenotypic markers, however, the 
reality is these are heterogeneous products; different product cell types, derived from different cell 
sources using different protocols. The precision or resolution of characterisation required for safe 
translation to correlate with both clinical and pre-clinical efficacy will require expert scientific advice 
and delegates were clear that developers will need to give regulators confidence in their knowledge 
of the populations of cells in question. This knowledge will inevitably grow with experience with 
clinical products and manufacturers are encouraged by regulators to establish robust scientific 
characterisation of starting materials and product. This will enable more refined correlation of product 
characteristics with clinical outcome over time and resolve critical factors in the suitability of multiple 
cell lines for use in a common production process.  Furthermore, this knowledge will be necessary for 
product development and production at new manufacturing sites. 
7.2 Cell metrology 
 Cell cultures are frequently reliant on the skills of scientists who assess the “quality” of cells based on 
personal experience. Qualitative observations are required to assess various cell culture features such 
as the “health”, the degree of “confluency” of a particular cell culture and the levels of markers 
expressed by certain cells. These are crucial to monitoring the bioprocess safety as changes in 
morphology, appearance and growth rate may all relate to issues for the product. Further, many 
analytical technologies such as gene expression and genetic stability techniques provide a result 
representative of the culture as a whole and do not generally reveal minor sub-populations which may 
expand in culture, requiring in-process monitoring to assure product acceptability. Of course, at 
certain levels such populations may direct product rejection or purification.  Approaches are beginning 
to be developed to qualify both cell images and fluorescence and that will play an important part in 
process monitoring (Heslop et al., 2015). 
7.3 Function (fitness-for-purpose) versus identity 
In the absence of reliable functional assays predictive of ultimate performance, cellular markers are 
often nominated as surrogates of functionality. However, these may not be directly linked to the 
desired activity or potency required for the intended product. The critical cell subpopulations or 
differentiation  pathways may not be known and changes due to processing could result in decreased 
potency whilst sustaining surrogate markers of function as observed for MSCs, as shown for example, 
by Binato et al. (2013). It is therefore imperative that manufacturers understand the biology of the 
system with which they are working and establish ongoing work to develop functional assays which 
reveal the true elements of therapeutic function. These issues are especially important for the long 
differentiation protocols required to establish hPSC derived products. Delegates believed that a 
specification with tolerances can be set for each product by knowing how many cells are efficacious 
and accepting a range of function to give a positively beneficial clinical outcome to patients. 
7.4 Multiple cell banks for common production purposes. 
There are now many proposals to produce a large number of iPSC lines to enable patient matched 
tissue products. If each of these cell lines were to be viewed as a distinct starting material and 
therefore the medicinal products derived from each cell bank similarly viewed as a separate and 
distinct product, then preclinical and clinical testing of each cell line would be required. This would 
prove costly and time consuming and could prevent the development of such therapies. It was 
concluded that satisfactory characterisation and meeting a common specification for each of the 
original cell lines and subsequent banks should be sufficient for acceptability for use of these cells as 
starting materials for a range of finished medicinal products.  These products, in turn, would be 
required to meet in process and finished product specification and to perform satisfactorily in 
preclinical and clinical trial(s). This would allow products to be generated from multiple cell lines for 
the trial and subsequent marketing of the final medicinal product. This approach for iPSC derived 
therapies will require further investigation to identify the required set of comparability criteria that 
would provide scientific justification for development of such products. 
8 Regulatory Review is a Process. 
This is a young field and the key message received from UK regulators present was that RMT 
developers should seek early engagement and in the UK this can be made through the UK Medicines 
Hand Healthcare products Regulatory Authority’s Innovation office and ‘One Stop Shop’ (website 4). 
Furthermore, delegates agreed that there was clear benefit for smooth delivery of new trials and 
products, through ongoing engagement and dialogue throughout the process of developing new 
products. In conclusion, regulatory engagement is advised at all key stages in the product lifecycle. 
As with other biological medicines, biological reference materials are required to demonstrate 
product consistency. These may be either living biological materials or stable reference materials. 
Workshop delegates concurred that complexity and variability of cell-based medicines mean that 
reference materials for final product monitoring will probably be product specific and the potential 
for generic reference materials may be limited, although it would be valuable for control of analytical 
methods used to characterise those products. 
9 Conclusions 
There are new challenges for RMTs where there are few directly applicable solutions transferable from 
more conventional products.  Raw and starting materials are now receiving support from regulatory 
and scientific guidance documents which will be of assistance to manufacturers. Robust product 
characterisation is vital to reveal and understand the key features of a product that enable the 
manufacturer to demonstrate its safety and reproducibility and to provide improvements in the 
manufacturers’ ability to measure potency.  A good scientific understanding of the product 
characteristics by the manufacturer is a key issue for regulators and it is recommended that they 
should engage with the regulator from early product development to development of final 
formulation of final release tests, and also during ongoing product improvement based on correlation 
of characterisation and clinical outcomes. It is clear that we are breaking new ground both in terms of 
basic science and regulatory science. There is therefore a need for regular iterations between the 
scientific, manufacturing and regulatory communities. It is also important to share new safety 
concerns, and to be clear about uncertainties which cannot be fully resolved at the present time, and 
therefore must be part of the risk management plan for a new product. The ongoing programme of 
UK RMP workshops will continue to lead discussion on these topics and promote learning from the 
experiences of existing manufacturers. 
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Glossary of critical terms 
Raw materials 
European directive 2001/83 EC , the community code relating to medicinal products for human use, as ‘Any 
other substances used for manufacturing or extracting the active substance(s) but from which this active 
substance is not directly derived, such as reagents, culture media, foetal calf serum, additives, and buffers 
involved in chromatography, etc… ‘.  
 
Starting materials 
Raw materials are distinct from starting materials which are defined in the same European Directive as ‘… all the 
materials from which the active substance is manufactured or extracted…….For biological medicinal products, 
starting materials shall mean any substance of biological origin such as micro-organisms, organs and tissues of 
either plant or animal origin, cells or fluids (including blood or plasma) of human or animal origin, and 
biotechnological cell constructs (cell substrates, whether they are recombinant or not, including primary cells).’ 
 
 
